News

Dana-Farber/Boston Children's nation’s #1 pediatric cancer program

U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new 2019-20 Best Children’s Hospitals rankings.

Children with cancer wait an average of 6.5 years longer than adults to access new targeted drugs, finds study at Dana-Farber/Boston Children’s

Researchers call for expanding children’s access to experimental cancer therapies

Team led by Dana-Farber/Boston Children’s Kimberly Stegmaier receives SU2C Sharp Award from Stand Up To Cancer

Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.

Researchers at Dana-Farber/Boston Children's and UMass Medical School optimize gene editing for sickle cell disease and beta thalassemia

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases, sickle cell disease and beta thalassemia, applying CRISPR-Cas9 gene editing to patients' own blood stem cells.

Dana-Farber/Boston Children's Brian D. Crompton, MD, awarded research grant by the Go4theGoal Foundation

The Go4theGoal Foundation (G4TG) recently awarded Brian Crompton, MD, of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a $50,000 research grant.

Fishing for new leads in rare mucosal melanoma

Vector reports that zebrafish are helping scientists dissect intricate molecular pathways in cancer and discover new treatment approaches.

Dana-Farber and Boston Children’s Hospital teams win Moonshot grants

The federal Beau Biden Cancer Moonshot program has awarded two grants of $2.5 million over five years to two research teams led by scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

In zebrafish, a way to find new cancer therapies, targeting tumor promoters

Vector reports on a new study that finds that retinoic acid, best known as an acne treatment, may also be effective in treating adenoid cystic carcinoma.

Dana-Farber/Boston Children's again ranked among the top national pediatric cancer programs

U.S. News & World Report has ranked Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #3 in the nation in its new 2018-19 Best Children's Hospitals report.

Pioneering hematologist to receive 2018 Nemmers Prize in Medical Science

Stuart H. Orkin, MD, an investigator of the Howard Hughes Medical Institute at Boston Children’s Hospital and Dana-Farber Cancer Institute and professor at Harvard Medical School known for his landmark discoveries into blood cell development and the genetic basis of blood disorders, is the recipient of the 2018 Mechthild Esser Nemmers Prize in Medical Science at Northwestern University.